• Intelligent Bio Solutions reported completed U.S. clinical study results for its fingerprint-based drug screening system targeting codeine.
• Findings showed stronger overall performance versus its prior study, supporting reliability across multiple clinical sites.
• Data collection is finished, clearing a key hurdle for a planned FDA 510(k) submission in September 2026.
• Management expects the filing to support planned entry into the U.S. market following FDA clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010831PRIMZONEFULLFEED9819142) on September 01, 2026, and is solely responsible for the information contained therein.